IT Type
Peptide-based IT
Description
DT389-GRP is a fusion protein containing the first 389 residues of DT fused to gastrin releasing peptide GRP via a linker. Gastrin-releasing peptide is a regulatory human peptide that can cause gastrin to release and regulate gastric acid secretion and intestinal motor function. The ganglion fibers of the vagus nerve innervating gastric G cells release GRP, and GRP stimulates G cells to release gastrin. According to multiple studies, GRP receptors are upregulated on the surface of different malignant cell types, including cell lines of small cell lung cancer, breast cancer, prostate cancer, and colon cancer. DT389-GRP has a good correlation between GRP levels and toxicity in the small cell lung cancer cells tested.
Indication
Brest cancer, prostate cancer, colon cancer
Classification
Immuntoxin; biobetter
Construction
DT389-GRP
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop our ADCC/CDC-enhanced antibodies or immutoxins. For commercial partners interested in our therapeutic biobetter product, Creative Biolabs welcomes collaboration.
Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
GRP
Full Name
Gastrin Releasing Peptide
Background
This gene encodes a member of the bombesin-like family of gastrin-releasing peptides. The encoded preproprotein is proteolytically processed to generate two peptides, gastrin-releasing peptide and neuromedin-C. These peptides regulate numerous functions of the gastrointestinal and central nervous systems, including release of gastrointestinal hormones, smooth muscle cell contraction, and epithelial cell proliferation. These peptides are also likely to play a role in human cancers of the lung, colon, stomach, pancreas, breast, and prostate. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed. [provided by RefSeq, Jan 2016]
Alternative Names
Gastrin Releasing Peptide; Gastrin-Releasing Peptide; Neuromedin C; Prepro-GRP; Bombesin; Pre-Progastrin Releasing Peptide;
Gene ID
Entrez Gene: 2922
UniProt ID
UniProtKB: P07492
Antibody Indication
Brest cancer, prostate cancer, colon cancer
Peptide
GRP peptide
Toxic Moiety
DT389
Organism
Corynebacterium
Family
Diphtheria toxin
Toxic MOA
Diphtheria toxin kills cells by inhibiting eukaryotic protein synthesis, and its mechanism of action has been extensively characterized. This potent toxin inactivates elongation factor (EF-2) required for protein synthesis. Specifically, diphtheria toxin transfers the ADP-ribose moiety of NAD to EF-2, and thus blocks the translational machinery of target cells.
Brest cancer, prostate cancer, colon cancer
